Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2)
Sponsor: Astellas Pharma Global Development, Inc.
A observational or N/A phase clinical study on Age-Related Macular Degeneration and Geographic Atrophy, this trial is completed. The trial is conducted by Astellas Pharma Global Development, Inc. and has accumulated 21 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
21 versions recorded-
May 4, 2026 — Present [daily]
Completed
-
Apr 16, 2026 — May 4, 2026 [daily]
Completed
Phase: PHASE3 → None
-
Sep 2025 — Apr 2026 [monthly]
Completed PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Jun 2025 — Aug 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 16 earlier versions
-
Jan 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Mar 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Sep 2023 — Feb 2024 [monthly]
Enrolling By Invitation PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Enrolling By Invitation PHASE3
-
May 2023 — Jun 2023 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2023 — May 2023 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2023 — Apr 2023 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2022 — Feb 2023 [monthly]
Enrolling By Invitation PHASE3
First recorded
Eligibility Summary
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).
Contact Information
- Astellas Pharma Global Development, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .